A Phase III Clinical Trial Evaluating DCVax-L Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
- Indications Brain cancer; Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors Northwest Biotherapeutics
- 31 May 2018 According to a Northwest Biotherapeutics media release, interim data will be discussed the ASCO Conference 2018.
- 29 May 2018 Results presented in the Northwest Biotherapeutics Media Release.
- 29 May 2018 According to a Northwest Biotherapeutics media release, interim survival data were published in the Journal of Translational Medicine.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History